Home → News → Clinical Trials → Archive

Clinical Trial News Archive

Get news By email or subscribe to our News feeds.

All News Consumer Pharma New Drugs Pipeline Clinical Trials

February 2012

February 1

Dendreon Announces Presentation of PROVENGE Data at the ASCO 2012 Genitourinary Cancers Symposium Medivation and Astellas Announce Positive Results From the Phase 3 AFFIRM Trial of MDV3100 in Prostate Cancer Patients Who Received Prior Chemotherapy Experimental Neurology Journal: BrainStorm's NurOwn Stem Cell Technology Shows Promise for Treating Huntington's Disease Aethlon Medical Reports Immediate and Rapid Virologic Responses in Hepatitis C (HCV) Patients Receiving Hemopurifier Treatment Protocol AB Science Reports Positive Clinical Study Data: Masitinib Significantly Extends Overall Survival as compared to Pfizer's Sutent in Gleevec-resistant GIST ThermoGenesis Provides Update on Res-Q Clinical Evaluations at Leading Stem Cell Therapy Conference NIH Launches Trials To Evaluate CPR And Drugs After Sudden Cardiac Arrest

February 2

Phase 1 Study of OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Shows Early Evidence of Activity in Bladder Cancer Clinical Data on OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence of Hsp27 as a Potential Therapeutic Target in Advanced Prostate Cancer Clinical Data on OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence of Hsp27 as a Potential Therapeutic Target in Advanced Prostate Cancer International Phase I Trial Results of Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) Show All Pharmacokinetic Parameters Significantly Improved in Patients With Severe Hemophilia B Cannabis Science Reports Success For 4th Brand New Self-Administering Cancer Patient International Phase I Trial Results of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) Show All Pharmacokinetic Parameters Significantly Improved in Patients with Severe Hemophilia B Compugen Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy Lubiprostone Meets Primary Endpoint in Phase 3 Clinical Trial for Opioid-Induced Bowel Dysfunction (OBD) Diamyd Medical's Phase III Study Published in The New England Journal of Medicine

February 7

Clinical Results from Aduro's Phase 1 Trials Published in Clinical Cancer Research Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar New Study Evaluates Cialis in parallel with Tamsulosin in Men with Signs and Symptoms Suggestive of Benign Prostatic Hyperplasia Anacor Pharmaceuticals Announces Positive Preliminary Results from Two Safety Studies of AN2728 and Updates Atopic Dermatitis Results and Regulatory Status Thrasos and Collaborators Publish Nature Medicine Research Article Detailing Potential Treatment Approach for Kidney Disease Cannabis Science Awaits Full Biopsy Report As Newest Series of Photos Shows Cancer Lesion Evidently Completely Killed & Hair Re-growth Begins On New Healthy Skin From 2nd Self-Administering Cancer Patient Jennerex Publishes Data on JX-594 Cancer Targeting Mechanisms Omeros Provides Update on Ongoing OMS302 Phase 3 Clinical Trial

February 8

Pivotal Study Published in JAMA Confirms Potential of Novartis Candidate Vaccine Bexsero to Help Protect Infants Against Devastating Meningococcal Serogroup B Disease Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase III Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain Four-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Sustained or Continued Improvement Across All Endpoints Halting Bone-Building Osteoporosis Drug Use Cuts Risk for Additional Atypical Femur Fracture in Half Conclusive Results of Regulatory Toxicology Studies With Gft505

February 14

PROLOR Biotech Announces Positive Preclinical Results from Comparative Study of its Long-Acting Clotting Factor VIIa Injectable Treatment for Blood Clots in Advanced Cancer Patients Increases, According to New Research Gene Signal and Collaborators Demonstrate Successful Activity of Topical Aganirsen in Models of Retinal Neovascular disease Is lack of VTE protocol adherence putting cancer patients at risk? New study looks at the problem. Sirona Biochem Announces Results in Key Study for Biological Inducer SuppreMol releases positive interim Phase Ib/IIa results on SM101 in Primary Immune Thrombocytopenia (ITP) trials AiCuris Drug Letermovir (AIC246) Meets Primary Efficacy Endpoints in Phase 2 For Human Cytomegalovirus (HCMV) Prophylaxis in Human Blood Precursor Cell Recipients Phase 3 Data on HEPLISAV in Adults Aged 18-55 Published in VACCINE

February 21

Innocoll Announces Successful End-of-Phase 2 Meeting with FDA for XaraColl® and Agreement of the Phase 3 Program BioLineRx Announces Publication of Pre-Clinical Results Demonstrating Efficacy of BL-7010, an Oral Treatment for Celiac Disease and Gluten Sensitivity Threshold Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results of TH-302 in Patients With Pancreatic Cancer IntelliCell BioScience Inc. Procedure Enables Norwegian Star Basketball Player to Fully Recover from Patella Tendinitis to Play for Manhattan College Amsterdam Molecular Therapeutics Receives Request for Further Information From CHMP on Glybera Mayo Clinic: Prediabetes May Not Explain Diabetic Polyneuropathies Soligenix Announces Positive Survival Results of SGX202 in Radiation Injury Repligen Announces FDA Grant of Priority Review for SecreFlo NDA Oral Treprostinil New Drug Application Accepted by FDA for Review

February 23

FDA Advisory Committee Recommends Approval of Qnexa Gel-Forming Vaginal Tablet Helps To Control Spread Of AIDS FDA Accepts Impax Pharmaceuticals NDA Filing for IPX066 for the Treatment of Idiopathic Parkinson's Disease PROLOR Biotech to Present Preclinical Data on Its Long-Acting Clotting Factors VIIa and IX at European Hemophilia Conference Vertex Announces 12-Week On-Treatment Data and SVR4 From Phase 2 Study of Interferon-Free (All-Oral) Treatment Regimen of INCIVEK, VX-222 and Ribavirin in People with Genotype 1 Hepatitis C Pfizer Statement Regarding CDC's ACIP Discussion of Prevnar 13 for Use in Adults Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis Cannabis Science Presents Newest Case Photos of the 3rd Critical Squamous Cell Carcinoma Self-Medicated Cannabis Patient with Clear Continued Improvement Obesity Care Continuum (OCC) Applauds FDA Advisory Committee Resounding Approval of QNEXA

February 24

Active Biotech and Ipsen Report Tasquinimod (TASQ) Phase II Long Term Safety Data at the 27th European Association of Urology (EAU) Congress FDA Advisory Panel Recommends Approval of Chelsea's Northera(droxidopa) for the Treatment of Symptomatic Neurogenic OH SNBL USA to Host Developmental Toxicology Session at the 2012 SOT Annual Meeting and ToxExpo in San Francisco, CA Forest and Almirall Announce Positive FDA Advisory Committee's Recommendation for Approval of Aclidinium Bromide for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) Dual Inhibition of MET and VEGF Signaling With Cabozantinib Blocks Tumor Invasiveness and Metastasis Millennium Research Institute and UC San Diego Present Data on Pain Treatment at American Academy of Pain Medicine Annual Meeting A Different Approach to Lumbar Epidural Steroid Injections Improves the Quality of Life and Everyday Functionality in Patients with Low Back Pain

February 27

Phase 2 Data of Takeda?s Investigational GPR40 Agonist, Published in The Lancet, Demonstrated Improved Glycemic Control in Patients with Type 2 Diabetes BioSante's Pancreas Cancer Vaccine Shows over 60% Survival Increase in Newly Presented Study Watson Receives Complete Response Letter from FDA for Progesterone Vaginal Gel 8% Advaxis Low Dose Cohort 1 Meets 50% Efficacy Target In CIN 2/3 Octapharma USA Submits BLA for octaplasLG, a Therapy Targeting Adverse Transfusion Events Nature: BrainStorm's NurOwn Stem Cell Technology Offers Hope for Treating Huntington Disease Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting Statins Linked with Lower Depression Risk in Heart Disease Patients Generex Subsidiary Antigen Express to Present at Prestigious Cancer Immunotherapy Summit OncoGenex Announces Data Highlighting OGX-427 at 27th Annual European Association of Urology Congress OncoGenex Announces Data Highlighting OGX-427 at 27th Annual European Association of Urology Congress Study Links the Risk of Hypogonadism in Men to Long Acting Opioids in Patients Using Daily Opioid Therapy for Chronic Noncancer Pain

February 29

Synta Announces Review of Ganetespib Results in Lung Cancer Presented at IASLC 12th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting NW Bio to Present at the Cancer Immunotherapy Summit New Publication Describes Allon's davunetide as the Most Advanced Global Drug Candidate for PSP Groundbreaking Research Reveals Powerful Protective Immunity Mediated by T cells in Skin and Supports TREM Rx's Approach to Deliver Novel Vaccines to the Skin Phase 2b Trial Shows Unique Lipid Efficacy Profile of Novel Compound to Reduce Elevated Triglyceride Levels Clinical Development Program receives FDA "Fast Track Designation" and encouraging phase Ib safety results for Viaskin Peanut Mitochondrial Dysfunction Present Early in Alzheimer's, Before Memory Loss Phase III studies of Jakafi (ruxolitinib) published in The New England Journal of Medicine Demonstrate Significant Clinical Benefit for Patients with Myelofibrosis RADARS System Study Indicates Low Rates of Abuse for tapentadol IR

Clinical Trial Results Archive

2005

April

More News Resources

(web6)